|
AUPO203996A0
(en)
*
|
1996-08-30 |
1996-09-26 |
Novogen Research Pty Ltd |
Therapeutic uses
|
|
US6426334B1
(en)
*
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
|
ES2233426T3
(es)
*
|
1999-08-13 |
2005-06-16 |
Hybridon, Inc. |
Modulacion de la estimulacion inmunitaria medida por cpg de oligonucleotido por modificacion de la posicion de los nucleosidos.
|
|
US6899891B2
(en)
*
|
1999-12-16 |
2005-05-31 |
Harry J. Siskind |
Nutritional composition, methods of producing said composition and methods of using said composition
|
|
CA2398432C
(en)
*
|
2000-01-26 |
2012-06-19 |
Hybridon, Inc. |
Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
|
|
AU2001257366B2
(en)
|
2000-05-01 |
2006-03-16 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
WO2003084527A1
(en)
*
|
2002-04-08 |
2003-10-16 |
Takeda Chemical Industries, Ltd. |
Severe sepsis preventive therapeutic agent
|
|
US20040009949A1
(en)
*
|
2002-06-05 |
2004-01-15 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
|
|
SE0201701D0
(sv)
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
|
EP1393745A1
(en)
|
2002-07-29 |
2004-03-03 |
Hybridon, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
|
|
WO2004094671A2
(en)
|
2003-04-22 |
2004-11-04 |
Coley Pharmaceutical Gmbh |
Methods and products for identification and assessment of tlr ligands
|
|
EA200600069A1
(ru)
|
2003-06-20 |
2006-08-25 |
Коли Фармасьютикал Гмбх |
Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
|
|
EP1648913A4
(en)
*
|
2003-07-15 |
2008-09-10 |
Idera Pharmaceuticals Inc |
SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
|
|
EP1697389A4
(en)
*
|
2003-10-24 |
2008-12-24 |
Eisai R&D Man Co Ltd |
COMPOUNDS AND METHODS FOR TREATING ILLNESS AND SUFFERING TOLL-LIKE RECEPTOR 2 RELATED DISORDERS
|
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
|
GB0329146D0
(en)
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
JP2007534775A
(ja)
*
|
2004-05-28 |
2007-11-29 |
セダーズ−シナイ メディカル センター |
脈管の疾患を処置するための方法
|
|
NZ553581A
(en)
*
|
2004-09-01 |
2011-04-29 |
Dynavax Tech Corp |
Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
|
|
WO2006063072A2
(en)
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
|
WO2006066003A2
(en)
*
|
2004-12-17 |
2006-06-22 |
Dynavax Technologies Corporation |
Methods and compositions for induction or promotion of immune tolerance
|
|
US20060257411A1
(en)
*
|
2005-05-06 |
2006-11-16 |
Bruce Beutler |
Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
|
|
EP1928500A2
(en)
|
2005-09-27 |
2008-06-11 |
Coley Pharmaceutical GmbH |
Modulation of tlr-mediated immune responses using adaptor oligonucleotides
|
|
US8399423B2
(en)
*
|
2005-10-12 |
2013-03-19 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
US8383598B2
(en)
*
|
2005-10-12 |
2013-02-26 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
US8426375B2
(en)
*
|
2005-10-12 |
2013-04-23 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
WO2007047396A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
US8377898B2
(en)
*
|
2006-10-12 |
2013-02-19 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
CA2694973A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Idera Pharmaceuticals, Inc. |
Toll like receptor modulators
|
|
AU2008317261B2
(en)
*
|
2007-10-26 |
2015-04-09 |
Dynavax Technologies Corporation |
Methods and compositions for inhibition of immune responses and autoimmunity
|
|
US20090131512A1
(en)
*
|
2007-10-31 |
2009-05-21 |
Dynavax Technologies Corp. |
Inhibition of type I in IFN production
|
|
WO2009154609A1
(en)
*
|
2008-06-17 |
2009-12-23 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
US11114308B2
(en)
|
2018-09-25 |
2021-09-07 |
International Business Machines Corporation |
Controlling of height of high-density interconnection structure on substrate
|
|
US11116008B2
(en)
|
2018-11-02 |
2021-09-07 |
Samsung Electronics Co., Ltd. |
Method and device for radio resource allocation in wireless communication system
|
|
TWI711225B
(zh)
|
2019-07-01 |
2020-11-21 |
唐虞企業股份有限公司 |
連接器總成
|